NL-OMON44633已完成不适用
A clinical study to evaluate the safety, tolerability, and pharmacokinetics of the MMP 12 inhibitor FP- 025 after multiple oral ascending dose administration, and to evaluate the effect of food after a single oral dose administration in healthy subjects - CS0284-170114
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Males or females aged *18 and 65 years, with a BMI *18 kg/m2 and 30 kg/m2. Female subjects must be of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation, hysterectomy or bilateral oophorectomy; or as post-menopausal females defined as 12 months amenorrhoea and follicle stimulating hormone (FSH) levels >40 IU/L.
- •2. A resting pulse *40 bpm and *100 bpm at screening and on Day -1.
- •3. A resting systolic blood pressure of 150 mmHg and a resting diastolic blood pressure of 95 mmHg at screening and on Day -1.
- •4. Baseline laboratory test values within reference ranges based on the blood and urine samples taken at screening and on Day -1. Out of normal ranges values may be accepted by the Investigator, if not clinically significant.
- •5. The subject is, in the opinion of the Investigator, generally healthy based on assessment of medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the haematology, clinical chemistry, urinalysis, serology, and other laboratory tests.
- •6. The subject must use adequate contraception, if applicable, during the study and until 3 months after completion of the study.
- •7. Subjects participating in the FE part of the study must be willing and able to consume the entire high-fat, high-calorie breakfast in the designated timeframe.
- •8. Signed Informed Consent prior to any study related procedures.
- •9. Ability to communicate well with the Investigator, in the local language, and to understand and comply with the requirements of the study.
排除标准
- •1. The subject has taken prescription or non-prescription medication, herbal remedies, vitamins or minerals within 2 weeks prior to the first dose of study product (or within 5 half-lives prior to inclusion for any medication ingested, whichever is longer).
- •2. The subject has a substance abuse-related disorder or has a history of drug, alcohol and/or substance abuse deemed significant by the investigator.
- •3. The subject has taken any investigational products within 60 days prior to the first dose of study product.
- •4. The subject has a history of severe drug allergy or hypersensitivity or food allergy.
- •5. The subject has a history or presence of any clinically significant immunological, cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (in particular diabetes or pre-diabetes), haematological, dermatological, venereal, neurological, chronic infectious or psychiatric disease or other major disorder.
- •6. The subject has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, which has not been in remission for at least 5 years prior to the first dose of study product.
- •7. The subject has a history of abdominal surgery (excluding laparoscopic cholecystectomy or uncomplicated appendectomy) or thoracic or non-peripheral vascular surgery within 6 months prior to the first dose of study product.
- •8. The subject has any concurrent illness that may affect the particular target or absorption, distribution, and elimination of the study product.
- •9. The subject has had a clinically significant illness within 4 weeks prior to the first dose of study product.
- •10. The subject has had surgery or trauma with significant blood loss within the last 3 months prior to the first dose of study product.
- •11. The subject has donated blood more than 250 mL within 2 months prior to the first dose of study product.
- •12. The subject has tested positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV).
- •13. The subject is a current smoker or uses other nicotine containing products. Ex-smokers must have ceased smoking at least 6 months prior to the first dose of study product.
- •14. The subject has tested positive at screening or on Day 1 for drugs of abuse or alcohol.
- •15. A female subject who has a positive pregnancy test at screening or on Day 1.
- •16. The subject*s corrected QT interval (QTcF) (Fridericia*s correction) is >450 ms as read on the printout of the ECG produced by the ECG equipment and evaluated by the Investigator at screening and on Day -1. An out-of-range or abnormal ECG may be repeated. In total, 3 ECGs should be recorded consecutively and the Investigator must evaluate the triplicate ECG. If the subject*s QTcF is >450 ms on at least 2 ECGs, the subject must be excluded.
- •17. In general, subjects should refrain from excessive physical exercise and strenuous sports activities (endurance sports) for at least 4 days before screening and Day -1.
- •18. The subject is, in the opinion of the Investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason.
- •19. Legal incapacity or limited legal capacity at screening and on Day -1.
- •20. Employees of the Investigator or study centre, as well as first degree family members of the employees or the Investigator.
研究者
相似试验
招募中
不适用
safety and effectiveness of Soreze gel in pressure ulcerCTRI/2021/06/034297Amaterasu Lifesciences
未知
2 期
A study to evaluate ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Japanese adults with chronic Hepatitis C Virus infectioJPRN-jRCT2080221883AbbVie GK96
已完成
不适用
A clinical trial to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of LEO 153339 in healthy subjectsPsoriasisNL-OMON51974eo Pharma A/S134
尚未招募
1 期
A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adultsovel Coronavirus Pneumonia (COVID-19)ITMCTR2000003169anjing University
已完成
2 期
Clinical study to investigate safety, tolerability, efficacy,pharmacokinetics and pharmacodynamics of inhaled multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with moderate to severe COPD– A randomised, double-blind, parallel group, multicenter, phase IIa pilot study –J44.9Chronic obstructive pulmonary disease, unspecifiedDRKS00006087Philipps-Universität Marburg19